Phase 2 Evidence and Impact Analysis
All 45 articles reviewed; 45 included in analysis. All abstracts only (no PMC full text). Scores reflect independent judgment applied to triage metadata.
Article-by-Article Scoring
Article 1 — Wang et al. (2026) | PMID 42888434
Decoding coupled epigenetic-fragmentomic signals in cfDNA for cancer diagnosis 🔴 Early cancer detection or prevention
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Integrating methylation haplotype blocks (MHBs) with fragmentomics in a single cfDNA assay is a meaningful methodological advance; not purely incremental |
| Clinical Relevance | 7 | Multi-modal cfDNA approach could improve cancer detection specificity; interpretability angle is clinically meaningful but not yet outcome-validated |
| Population Reach | 8 | Pan-cancer liquid biopsy relevance; broad applicability if validated |
| Implementation Speed | 5 | Requires WGS infrastructure; bioinformatics pipeline maturation needed |
| Evidence Strength | 6 | Prospective multi-modal validation — strongest design in this batch for this topic — but abstract-only limits full appraisal; sample size unknown |
Key quantitative result: Not extractable from abstract — MHBs established as interpretable units; no sensitivity/specificity figures reported. External validation: Not explicit; described as prospective validation but single-study. Main limitation: Sample size and cancer-type scope unknown; abstract-only access; no clinical endpoint (e.g., survival, lead-time benefit). Equity implications: Benefits primarily those with access to WGS-capable clinical labs — a significant barrier in LMICs. Evidence Maturity: Validated → Revised to Exploratory/Early Validated — prospective design is encouraging but clinical utility metrics are absent from abstract.
Article 2 — Palaz et al. (2026) | PMID 42888855
Early HSCT in Type 1 Fucosidosis: Reversal of Central Tegmental Tract Abnormalities 🟠 Novel or significantly improved treatment
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | MRI-documentable reversal of central tegmental tract changes after HSCT in fucosidosis is genuinely novel; imaging biomarker of treatment response is new |
| Clinical Relevance | 7 | For this ultra-rare disease with no approved disease-modifying therapy, a case demonstrating neurological reversal is highly meaningful relative to unmet need |
| Population Reach | 3 | Fucosidosis affects <1:1,000,000; but scored relative to the affected population and unmet need, justifiably higher within that context |
| Implementation Speed | 4 | HSCT infrastructure exists; the bottleneck is early diagnosis, not transplant access — feasible within 3–5 years for identified patients |
| Evidence Strength | 3 | Single case report; exploratory by design; classification_confidence = medium |
Key quantitative result: Clinical improvement and resolution of MRI central tegmental tract abnormalities in one patient; no quantitative metrics available. External validation: None — single case. Main limitation: N=1; no control; natural history confounding; long-term follow-up absent. Equity implications: Ultra-rare disease disproportionately diagnosed late in LMICs; benefits primarily patients with access to metabolic newborn screening and transplant centers. Evidence Maturity: Exploratory — confirmed. Watchlist-appropriate.
Article 3 — Scheffer et al. (2026) | PMID 42888932
STADIA-HFpEF: Dapagliflozin in phenotypically stratified HFpEF without myocardial fibrosis 🟠 Novel or significantly improved treatment
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First RCT to phenotypically stratify HFpEF by fibrosis status before testing SGLT2i; addresses a critical gap in precision HF management |
| Clinical Relevance | 8 | Null result in a fibrosis-negative subgroup is clinically practice-shaping — it argues for biomarker-guided SGLT2i use, not blanket prescribing |
| Population Reach | 8 | HFpEF affects ~3 million in the US alone; fibrosis stratification could redirect millions of prescriptions |
| Implementation Speed | 6 | Dapagliflozin already approved; CMR/biomarker fibrosis stratification adds workflow complexity but is clinically available |
| Evidence Strength | 7 | Randomized crossover trial with mechanistic endpoints; crossover design limits generalizability but is appropriately powered for mechanistic questions |
Key quantitative result: No significant improvement in LV distensibility or relaxation; isolated improvement in LA conduit strain; numerical reductions in inflammatory biomarkers (no p-values available from abstract). External validation: None yet — single RCT. Main limitation: Crossover design may underestimate chronic effects; abstract-only; sample size unknown; fibrosis stratification method not specified. Equity implications: Patients without access to advanced cardiac imaging (CMR/biomarker fibrosis testing) may be unable to benefit from phenotypic stratification — a real-world access gap. Evidence Maturity: Potentially Practice-Changing — confirmed. This null result is the clinically important message.
Article 4 — Ferrero et al. (2026) | PMID 42888505
Prognostic Impact of Moderate Secondary Mitral Regurgitation After Optimized GDMT in HF ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Confirms prognostic significance of residual MR after optimized therapy; adds rigorous quantification to a debated question |
| Clinical Relevance | 8 | Direct implication for intervention timing; 2,468 patients with paired echo — strong denominator for clinical decision-making |
| Population Reach | 7 | Secondary MR is extremely common in HF; millions of patients globally |
| Implementation Speed | 7 | Echocardiographic surveillance is standard; findings are immediately applicable to follow-up protocols |
| Evidence Strength | 7 | Large prospective paired cohort; paired echocardiography design is methodologically strong for this question |
Key quantitative result: Residual moderate secondary MR at 12 months independently associated with increased long-term mortality and HF hospitalization (specific HR not available from abstract). External validation: Not reported but large prospective cohort provides internal robustness. Main limitation: Observational; potential residual confounding; definition of "optimized GDMT" not specified; abstract-only. Equity implications: Patients without access to serial echocardiography (rural, low-income settings) will miss this surveillance opportunity. Evidence Maturity: Validated — confirmed.
Article 5 — Fai et al. (2026) | PMID 42891032
Smart Speculum for Cervical Cancer Screening in Cameroon 🔴 Early cancer detection or prevention
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Locally manufactured, AI-integrated speculum for LMIC cervical screening is a meaningful innovation in device equity |
| Clinical Relevance | 8 | Addresses a critical infrastructure gap in cervical cancer screening in sub-Saharan Africa; direct pathway to prevention |
| Population Reach | 9 | Cervical cancer kills ~340,000 women/year globally; >85% of deaths in LMICs; this device targets the highest-burden populations |
| Implementation Speed | 6 | Local manufacturing is a key enabler; AI telemedicine workflow requires regulatory approval and training infrastructure |
| Evidence Strength | 6 | Paired comparative study in 81 women — adequate for feasibility/comfort endpoints; not powered for cancer detection outcomes |
Key quantitative result: Improved patient comfort and cervical visualization vs. traditional speculum in 81 women (no quantitative metrics available from abstract). External validation: None — single-center feasibility study. Main limitation: Small sample; no cancer detection efficacy endpoint; single site in Cameroon; implementation at scale requires infrastructure. Equity implications: Explicitly designed for underserved populations — this is the most equity-positive article in the batch. Women in rural sub-Saharan Africa stand to benefit most. Evidence Maturity: Validated → Revised to Exploratory/Promising — comfort and visualization outcomes validated at feasibility scale; clinical efficacy not yet demonstrated.
Article 6 — Marbán Calzón et al. (2026) | PMID 42891438
Asfotase Alfa in Hypophosphatasia: Three Real-World Cases (Spain) 🟡 Underserved populations
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Asfotase alfa is already approved; adds real-world Spanish data but does not advance mechanistic or clinical knowledge substantially |
| Clinical Relevance | 6 | Meaningful for clinicians managing this rare disease; confirms real-world effectiveness in a European context |
| Population Reach | 3 | Hypophosphatasia prevalence ~1:100,000; scored relative to unmet need |
| Implementation Speed | 7 | Drug is approved; findings support existing prescribing — immediately applicable |
| Evidence Strength | 3 | Three cases; no control; high risk of selection bias; exploratory only |
Key quantitative result: All three patients responded well to asfotase alfa with substantial symptom improvement (no quantitative outcome metrics available). External validation: Supported by prior registration trial data, though this study itself is not externally validated. Main limitation: N=3; no comparator; abstract-only; publication bias likely. Equity implications: Drug cost (>$1M/year) limits access globally; real-world data from Spain is useful for EU access advocacy but does not address global equity. Evidence Maturity: Exploratory — confirmed.
Article 7 — Du et al. (2026) | PMID 42890831
Electronic Frailty Index and Mortality in Older Adults: Systematic Review and Meta-Analysis 🟢 Near-term implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | eFI is established; meta-analysis adds quantitative rigor to the dose-response relationship but is not a new concept |
| Clinical Relevance | 7 | Graded mortality association supports immediate clinical use of eFI for risk stratification; clinically actionable |
| Population Reach | 9 | Global aging population; hundreds of millions of older adults in EHR-connected health systems |
| Implementation Speed | 8 | eFI is derived from existing EHR data — no new technology required; can be integrated into current systems |
| Evidence Strength | 7 | Systematic review/meta-analysis — highest-level design in this category; limitations depend on constituent studies |
Key quantitative result: Graded association between eFI-defined frailty severity and mortality (no pooled HR available from abstract). External validation: Meta-analytic by design — aggregates across multiple studies. Main limitation: Quality depends on heterogeneity of included studies; eFI definitions may vary; abstract-only. Equity implications: eFI benefits populations in well-resourced EHR systems; older adults in paper-record or fragmented-system settings cannot benefit directly. Evidence Maturity: Validated — confirmed. 🟢 Near-term implementable justified.
Article 8 — Baudry et al. (2026) | PMID 42888496
NT-proBNP Age-Adjusted Thresholds for Acute Heart Failure in ED: Meta-Analysis 🟢 Near-term implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Age-adjusted NT-proBNP thresholds are not new concepts, but this meta-analysis provides the most robust quantification to date |
| Clinical Relevance | 8 | Directly applicable to ED triage; age-adjusted thresholds outperform fixed thresholds across patient subgroups |
| Population Reach | 8 | Acute dyspnea is one of the most common ED presentations worldwide; millions of patients annually |
| Implementation Speed | 8 | NT-proBNP is already in routine use; threshold adjustment is a protocol-level change only |
| Evidence Strength | 7 | Systematic review/meta-analysis; consistent accuracy across patient characteristics is a strong finding |
Key quantitative result: ≤300 ng/L provides excellent rule-out; age-dependent thresholds superior for rule-in vs. fixed thresholds (no AUC/sensitivity/specificity available from abstract). External validation: Meta-analytic aggregation across existing studies. Main limitation: Abstract-only; heterogeneity across included studies likely; may not capture the most recent high-sensitivity assays. Equity implications: NT-proBNP is available in most high-income EDs; significant access gaps in LMICs where POC cardiac biomarker testing is limited. Evidence Maturity: Validated — confirmed. Supports guideline refinement.
Article 9 — Mansilla et al. (2026) | PMID 42888950
AI-Assisted EEG Categorization in Long-Term Monitoring: Comparable Accuracy, Marked Efficiency 🟢 Near-term implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | AI-assisted EEG reading is not new, but validation in long-term monitoring with an approved system and expert oversight model is a meaningful operational advance |
| Clinical Relevance | 7 | Improves workflow efficiency and diagnostic sensitivity in epilepsy monitoring — directly impacts patient care |
| Population Reach | 6 | Epilepsy affects ~50 million globally; long-term EEG monitoring is a high-volume subspecialty procedure |
| Implementation Speed | 7 | System already approved; expert-oversight model is implementable within existing neurophysiology workflows |
| Evidence Strength | 7 | Prospective validation on independent dataset — methodologically strong for an AI diagnostic study |
Key quantitative result: Improved interrater reliability, efficiency, and diagnostic sensitivity vs. conventional interpretation (specific metrics not available from abstract). External validation: Independent dataset validation — a key strength. Main limitation: Abstract-only; generalizability across EEG systems and clinical contexts not established; AI system identity not specified. Equity implications: Benefits concentrated in high-income settings with access to long-term EEG monitoring infrastructure. Evidence Maturity: Validated — confirmed.
Article 10 — Pohlmann-Krappitz et al. (2026) | PMID 42890233
Peripheral Immune Profiles in Birdshot Uveitis 🟡 Underserved populations
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | High-dimensional mass cytometry characterization of BU is novel; disease-activity-dependent signatures add to sparse BU biomarker literature |
| Clinical Relevance | 5 | Potential for monitoring/treatment guidance but clinical utility not yet established; explicitly hypothesis-generating |
| Population Reach | 2 | Extremely rare (~1:300,000); scored relative to high unmet need within the affected population |
| Implementation Speed | 2 | Mass cytometry not in routine clinical use; translational gap is large |
| Evidence Strength | 4 | Cross-sectional; single-center; mass cytometry cohort; exploratory design |
Key quantitative result: Disease-activity-dependent immune signatures identified (no quantitative markers specified in abstract). External validation: None. Main limitation: Cross-sectional; no longitudinal validation; small likely cohort; abstract-only. Equity implications: Ultra-rare disease; benefits patients at specialist autoimmune uveitis centers only. Evidence Maturity: Exploratory — confirmed.
Article 11 — Muhtadi et al. (2026) | PMID 42890789
Circulating miRNAs for GBM Recurrence: Pilot Liquid Biopsy Study ⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | miRNA profiling for GBM recurrence monitoring is an active area; tumor-agnostic blood-based approach is moderately novel |
| Clinical Relevance | 5 | GBM has near-universal recurrence and limited monitoring options; blood-based complement to MRI is highly desirable but not yet validated |
| Population Reach | 4 | GBM incidence ~3/100,000; limited population reach but very high unmet need |
| Implementation Speed | 3 | Pilot study; independent cohort validation required before clinical use |
| Evidence Strength | 4 | Pilot study; small likely cohort; classification_confidence = medium |
Key quantitative result: miRNA profiles potentially complement imaging for longitudinal GBM monitoring (no AUC or accuracy metrics available). External validation: None — explicitly states validation required. Main limitation: Pilot study; no validation cohort; potential for overfitting; miRNA stability and standardization challenges. Equity implications: GBM affects a broad demographic; liquid biopsy monitoring could reduce imaging burden if validated. Evidence Maturity: Exploratory — confirmed.
Article 12 — Gecici et al. (2026) | PMID 42889918
Genomic Predictors of Intracranial Progression After Brain Metastasis Resection ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Molecular profiling of brain metastases for recurrence prediction is an evolving area; this study adds data but is not a conceptual breakthrough |
| Clinical Relevance | 5 | Retrospective; risk stratification hypothesis only; needs prospective validation before clinical use |
| Population Reach | 5 | Brain metastases occur in ~200,000 new US patients/year — moderate reach |
| Implementation Speed | 3 | Retrospective; requires prospective validation; NGS of resected metastases adds workflow complexity |
| Evidence Strength | 4 | Retrospective; single-institution likely; abstract-only; underpowered for histology-stratified analyses by self-admission |
Key quantitative result: Molecular profiling + clinical factors contributes to intracranial progression risk stratification (no specific ORs or HRs available). External validation: None — authors explicitly call for dataset expansion. Main limitation: Retrospective; single-institution; underpowered for subgroup analyses; abstract-only. Equity implications: NGS-based risk stratification benefits patients at academic centers with molecular profiling capabilities. Evidence Maturity: Exploratory — confirmed.
Article 13 — Sternheim et al. (2026) | PMID 42889942
Proximal Femoral Lesions in Cancer: Surgical Decision Tools Evaluation ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | CTFEA tool validation in this prospective context adds to sparse literature on surgical decision support |
| Clinical Relevance | 6 | Directly applicable to orthopaedic oncology decisions; CTFEA correctly identified all 4 fracture patients |
| Population Reach | 5 | Bone metastases occur in ~350,000 US patients/year |
| Implementation Speed | 4 | CTFEA requires computational infrastructure; prospective validation needed |
| Evidence Strength | 5 | Prospective with randomized allocation component; limited by sample size and abstract-only access |
Key quantitative result: CTFEA correctly identified all 4 fracture patients; prophylactic surgery did not affect survival time. External validation: Not reported. Main limitation: Small fracture event count (n=4); survival analysis confounded by cancer heterogeneity; abstract-only. Equity implications: Benefit concentrated at academic orthopaedic oncology centers; rural/community patients may not have access to advanced fracture prediction tools. Evidence Maturity: Exploratory — confirmed.
Article 14 — Lorenzo Monteagudo et al. (2026) | PMID 42890327
Oncological Clinical Trials in Primary Health Care in Cuba 🟡 Underserved populations
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | PHC-based cancer trial implementation is novel in the Cuban/LMIC context; model has broader applicability |
| Clinical Relevance | 5 | Demonstrates feasibility; no direct efficacy data on cancer treatments |
| Population Reach | 6 | Model applicable to LMICs globally; highly relevant for health equity in research access |
| Implementation Speed | 4 | Context-specific; requires political/institutional will and infrastructure |
| Evidence Strength | 3 | Longitudinal program evaluation; no comparator; abstract-only |
Key quantitative result: Positive impact on target population (no metrics available from abstract). External validation: None. Main limitation: No control group; context-specific (Cuban healthcare system); limited generalizability without further data. Equity implications: Strongly pro-equity — expanding research access in resource-limited settings; benefit to underserved populations is the primary purpose. Evidence Maturity: Exploratory — confirmed.
Article 15 — Wang et al. (2026) | PMID 42888915
EBV Association and Prognosis in Taiwanese Hodgkin Lymphoma ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Nationwide Taiwan dataset with US comparison adds meaningful epidemiological insight; EBV-HL biology in Asian populations is undercharacterized |
| Clinical Relevance | 5 | Informs surveillance strategies and EBV-targeted treatment considerations; not immediately practice-changing |
| Population Reach | 5 | HL is relatively rare; East Asian populations are underrepresented in HL research |
| Implementation Speed | 5 | EBV testing is standard; findings could be implemented in Taiwanese screening protocols |
| Evidence Strength | 5 | Retrospective multicenter cohort; nationwide scope is a strength; abstract-only |
Key quantitative result: HL incidence in Taiwan increased ~2.5-fold 2001–2020, particularly NS subtype in young women (from plain summary). External validation: US White comparison provides partial external context. Main limitation: Retrospective; EBV assessment method not standardized across sites; abstract-only. Equity implications: Benefits East Asian populations historically underrepresented in Western HL research. Evidence Maturity: Validated — confirmed.
Article 16 — Sim et al. (2026) | PMID 42890993
ctDNA Copy Number Variations for Prognosis in Head and Neck Cancer 🔴 Early cancer detection or prevention
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Tumor-agnostic LP-WGS for CNV detection in HNSCC plasma is methodologically innovative; avoids tissue-informed limitations |
| Clinical Relevance | 6 | Baseline CNB stratifies OS — a clinically meaningful prognostic signal if validated |
| Population Reach | 5 | HNSCC incidence ~65,000/year in the US; HPV-unrelated subgroup is the target |
| Implementation Speed | 3 | LP-WGS requires infrastructure; validation cohort needed before clinical use |
| Evidence Strength | 5 | Prospective longitudinal cohort — good design; limited by cohort heterogeneity and abstract-only access |
Key quantitative result: Baseline copy number burden (CNB) stratifies overall survival; LP-WGS enables tumor-agnostic CNV detection (no specific HR/AUC from abstract). External validation: Not reported; authors explicitly call for matched tumor sequencing validation. Main limitation: Heterogeneous cohort; matched tumor sequencing absent; abstract-only; needs larger validation. Equity implications: HNSCC disproportionately affects lower-income populations; tumor-agnostic approach could reduce barriers to ctDNA testing. Evidence Maturity: Exploratory — confirmed (triage "Validated" appears to be an error; design is prospective biomarker discovery, not clinical validation).
Article 17 — Wang et al. (2026) | PMID 42888543
AI in Rotator Cuff Diagnosis: Systematic Review ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Covers an active area but lacks primary data; review consolidates existing AI-RCT literature without adding new findings |
| Clinical Relevance | 5 | Highlights proof-of-concept value across the care pathway; explicitly states not clinically ready |
| Population Reach | 7 | Rotator cuff tears affect millions annually; high burden condition |
| Implementation Speed | 4 | Authors explicitly note routine clinical readiness is not established |
| Evidence Strength | 5 | Systematic review methodology; quality depends on constituent studies |
Key quantitative result: AI has proof-of-concept value; not yet clinically ready (no pooled metrics available). External validation: Meta-analytic by design. Main limitation: Narrative synthesis may limit pooled conclusions; heterogeneous AI applications across studies. Equity implications: If AI tools reduce reliance on subspecialist MRI readers, could benefit underserved communities. Evidence Maturity: Validated — confirmed (for the field assessment, though individual tools remain unvalidated).
Article 18 — Wang et al. (2026) | PMID 42890422
KRAS G12C-Mutant NSCLC: Mechanisms and Therapeutic Advances (Review) ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Narrative review of established KRAS G12C inhibitor landscape; synthesizes existing knowledge without new data |
| Clinical Relevance | 7 | KRAS G12C is now routinely tested and actionable; review is clinically useful for mechanism-guided sequencing decisions |
| Population Reach | 7 | KRAS G12C occurs in ~13% of NSCLC; lung cancer is the #1 cancer killer globally |
| Implementation Speed | 7 | Sotorasib/adagrasib are approved; review informs existing clinical practice |
| Evidence Strength | 4 | Narrative review; no primary data; no systematic methodology |
Key quantitative result: KRAS G12C occurs in ~13% of NSCLC (established figure); no new quantitative results. External validation: Not applicable (review). Main limitation: Narrative review; subject to author selection bias; rapidly evolving field may outpace publication. Equity implications: KRAS G12C testing requires NGS infrastructure; global access disparities in molecular testing remain a barrier. Evidence Maturity: Validated — confirmed for existing knowledge synthesis.
Article 19 — Chen et al. (2026) | PMID 42888605
Natural Teeth Count and Cognitive Impairment in Older Chinese Adults ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Tooth-cognition association is well-described; adds Chinese-specific longitudinal data (n=4,364) |
| Clinical Relevance | 4 | Observational; causality not established; study itself notes this limitation prominently |
| Population Reach | 7 | Cognitive impairment and tooth loss are highly prevalent in aging populations globally |
| Implementation Speed | 4 | Hypothesis-generating only; not implementation-ready |
| Evidence Strength | 5 | Longitudinal cohort; CLHLS database; n=4,364 is reasonable; but abstract-only and self-acknowledged non-causal |
Key quantitative result: Association between fewer natural teeth and cognitive impairment (no OR/HR available from abstract). External validation: Not reported. Main limitation: Observational; confounding not fully addressable; causality explicitly not established. Equity implications: Dental care access disparities mean tooth loss disproportionately affects lower-income older adults — an equity-relevant finding if causal links are confirmed. Evidence Maturity: Validated — confirmed for observational association; not for causality.
Article 20 — Wang et al. (2026) | PMID 42891112
GBD Study: Hematologic Malignancies and BMI in Asia, 1990–2023 ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | 33-year pan-Asian GBD analysis with Mendelian randomization for BMI-hematologic malignancy causation is a meaningful analytical contribution |
| Clinical Relevance | 6 | Directly informs regional cancer prevention policy; obesity-cancer link has treatment implications |
| Population Reach | 9 | Asia contains >4 billion people; hematologic malignancy burden is rising across the region |
| Implementation Speed | 5 | Policy implementation timeline; BMI prevention strategies are well-established but slow to scale |
| Evidence Strength | 6 | GBD methodology is robust; Mendelian randomization adds causal inference capability; abstract-only |
Key quantitative result: Rising hematologic malignancy burden in Asia; BMI causally linked via MR analysis (no specific risk estimates from abstract). External validation: GBD uses multiple validated data sources. Main limitation: GBD data quality varies by region; Mendelian randomization assumptions may not hold uniformly across diverse Asian populations. Equity implications: Findings most urgent in rapidly urbanizing Asian populations where obesity rates are rising rapidly; benefits from prevention programs would be broadly distributed. Evidence Maturity: Validated — confirmed.
Article 21 — Molteni et al. (2026) | PMID 42890328
HER2 Phenotyping of CTCs in Breast Cancer ⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Ratio-based CTC HER2 assessment capturing tumor heterogeneity beyond tissue biopsy is methodologically innovative |
| Clinical Relevance | 5 | Proof-of-concept for liquid biopsy HER2 monitoring; modest discriminative performance limits current utility |
| Population Reach | 7 | Breast cancer affects 2.3 million women annually worldwide |
| Implementation Speed | 3 | Proof-of-concept only; CTC enumeration not yet standardized beyond CellSearch; validation needed |
| Evidence Strength | 4 | Comparative observational; self-described as proof-of-concept; explicit limitation acknowledgment |
Key quantitative result: Ratio-based CTC HER2 assessment correlates with tissue HER2 but with modest discriminative performance (no AUC available). External validation: None — proof-of-concept. Main limitation: Modest discrimination; limited resolution in HER2-low range; abstract-only. Equity implications: If validated, liquid biopsy HER2 testing could replace repeat tissue biopsies — reducing burden on patients, particularly those in remote settings. Evidence Maturity: Exploratory — confirmed.
Article 22 — Xiao et al. (2026) | PMID 42888542
TyG-ABSI and TyG-WWI as Insulin-Resistance Mortality Markers ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | TyG-derived indices are emerging; this multi-cohort validation adds rigor but concept is not new |
| Clinical Relevance | 4 | Described as supplementary markers, not standalone tools; limited immediate clinical impact |
| Population Reach | 7 | Middle-aged and older adults with cardiometabolic disease — very large population |
| Implementation Speed | 5 | Low-cost calculation from routine labs; but clinical workflow integration requires validation |
| Evidence Strength | 5 | Multi-cohort with external survival validation — stronger than single-cohort; abstract-only |
Key quantitative result: TyG-related indices serve as interpretable CKM risk markers; not standalone predictors (no specific C-statistics available). External validation: External survival model validation included — a methodological strength. Main limitation: Observational; residual confounding; abstract-only; markers described as supplementary only. Equity implications: Low-cost markers accessible in resource-limited settings — a genuine equity advantage if validated. Evidence Maturity: Exploratory — confirmed.
Article 23 — Price et al. (2026) | PMID 42889535
Cardiovascular Risk After Risk-Reducing Salpingo-Oophorectomy (WHAM Study) 🟡 Underserved populations
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Prospective controlled data on CVD risk after RRSO in BRCA carriers is genuinely limited; this fills a real evidence gap |
| Clinical Relevance | 7 | Directly relevant to counseling BRCA1/2 carriers considering surgical prevention; null result for diastolic BP at 24 months is reassuring |
| Population Reach | 4 | BRCA1/2 carriers ~1:400; but population is proactively engaged with healthcare and decisions are high-stakes |
| Implementation Speed | 6 | Counseling change is immediate; monitoring protocol adjustment is feasible |
| Evidence Strength | 5 | Prospective controlled; aOR 1.03 (95% CI 0.48–2.18) for diastolic BP rise — adequately powered for primary endpoint; but abstract-only and observational |
Key quantitative result: aOR 1.03 (95% CI 0.48–2.18) for diastolic BP rise ≥5 mmHg at 24 months — no significant difference between RRSO and control groups. External validation: Not reported. Main limitation: 24-month follow-up may be too short for cardiovascular event ascertainment; abstract-only; observational cohort design. Equity implications: BRCA testing and RRSO are concentrated in high-income, White, well-insured populations; this evidence will not reach most BRCA carriers globally. Evidence Maturity: Exploratory — confirmed; 24-month cardiovascular risk data are preliminary.
Article 24 — Ding et al. (2026) | PMID 42889351
Gastric Cancer Molecular Subtyping via Extracellular Vesicle Characteristics ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | EV-related subtyping with endocytosis pathway focus adds a novel angle; but bioinformatics subtyping papers in gastric cancer are numerous |
| Clinical Relevance | 4 | Explicitly exploratory/hypothesis-generating; no clinical validation |
| Population Reach | 7 | Gastric cancer is the 5th most common cancer globally; very high incidence in Asia |
| Implementation Speed | 2 | Bioinformatics study; requires prospective biological and clinical validation |
| Evidence Strength | 3 | Bioinformatics only; no experimental validation; classification_confidence = medium |
Key quantitative result: EV-endocytosis subtypes linked to distinct biological and prognostic features (no specific metrics from abstract). External validation: None — computational only. Main limitation: Bioinformatics study; requires experimental and clinical validation; publication bias in subtype discovery literature. Equity implications: Gastric cancer disproportionately affects East Asian and low-income populations; improved subtyping could eventually benefit these groups. Evidence Maturity: Exploratory — confirmed.
Article 25 — Moritz et al. (2026) | PMID 42888922
U.S. Cervical Cancer Screening Rates by Age, Race, and Ethnicity, 2008–2023 ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Combined claims + survey methodology for screening rate estimation is methodologically sound; content is descriptive epidemiology |
| Clinical Relevance | 6 | Important for public health planning; reveals disparities in screening participation |
| Population Reach | 9 | All U.S. women eligible for cervical screening; cervical cancer is nearly 100% preventable with adequate screening |
| Implementation Speed | 7 | Findings directly inform public health programs and policy without additional validation |
| Evidence Strength | 6 | Multi-database methodology; strengths and limitations of claims + survey integration acknowledged |
Key quantitative result: National estimates of screening participation over 15 years by demographic (no specific rates from abstract). External validation: Cross-validated across claims and survey data sources. Main limitation: Claims data may undercount uninsured women; survey data subject to recall bias; abstract-only. Equity implications: Reveals racial and age-related disparities in cervical screening — directly informative for equity interventions. Women of color and low-income women are likely underserved. Evidence Maturity: Validated — confirmed.
Article 26 — Feng & Xie (2026) | PMID 42891596
Sacubitril/Valsartan in Elderly CAD + Hypertension: Retrospective Cohort ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Sacubitril/valsartan in HF is established; application to CAD+HTN without HF is a narrower extension |
| Clinical Relevance | 5 | Retrospective; limited by design; results need prospective confirmation |
| Population Reach | 7 | Elderly CAD+HTN is one of the most common clinical combinations globally |
| Implementation Speed | 4 | Drug is available; retrospective data not sufficient to change guidelines |
| Evidence Strength | 3 | Retrospective cohort; abstract-only; no sample size or effect sizes available |
Key quantitative result: Sacubitril/valsartan reduces long-term cardiovascular risk and improves BP control (no specific HR or event rates from abstract). External validation: None. Main limitation: Retrospective; indication bias likely; abstract-only. Equity implications: Drug cost and polypharmacy burden may limit access in elderly low-income patients. Evidence Maturity: Exploratory — confirmed.
Article 27 — Chen et al. (2026) | PMID 42891568
scRNA-Seq and Spatial Transcriptomics for Cervical Cancer Risk Stratification ⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Identification of a novel epithelial subcluster associated with early cervical carcinogenesis via spatial transcriptomics is genuinely novel |
| Clinical Relevance | 6 | If validated, biomarkers predicting LSIL progression could meaningfully improve colposcopy triage |
| Population Reach | 9 | Cervical cancer affects 600,000+ women/year globally; LSIL triage affects millions |
| Implementation Speed | 2 | Spatial transcriptomics is not a clinical tool; years of translational work required |
| Evidence Strength | 4 | Single-study integrative analysis; classification_confidence = medium; no clinical validation |
Key quantitative result: Novel epithelial subcluster identified; molecular markers enable LSIL risk stratification (no AUC/sensitivity available from abstract). External validation: None. Main limitation: Single study; no external cohort validation; spatial transcriptomics far from clinical implementation. Equity implications: If biomarkers are translated to accessible assays (e.g., PCR-based), could benefit women in LMICs most affected by cervical cancer. Evidence Maturity: Exploratory — confirmed (classification_confidence = medium).
Article 28 — Li et al. (2026) | PMID 42891603
ML for Predicting Cardiac MRI Motion Artifacts ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | ML for artifact prediction using psychological + physiological inputs is an interesting workflow innovation |
| Clinical Relevance | 5 | Reduces repeat scans; but limited to non-sedated CMR — a specific workflow context |
| Population Reach | 5 | CMR is performed in high-volume cardiac centers globally |
| Implementation Speed | 4 | Retrospective; needs prospective validation; nursing intervention protocol development required |
| Evidence Strength | 4 | Retrospective cohort; abstract-only |
Key quantitative result: Interpretable ML framework enables patient-specific artifact risk stratification (no AUC available from abstract). External validation: Not reported. Main limitation: Retrospective; single-center likely; limited generalizability. Equity implications: Could reduce repeat scans and radiation/cost burden; benefits concentrated in high-income CMR centers. Evidence Maturity: Exploratory — confirmed.
Article 29 — Cheng et al. (2026) | PMID 42888628
Frailty and Multisite Chronic Pain in Middle-Aged and Older Adults ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Frailty-pain association is established; mediation analysis via mental health adds modest novelty |
| Clinical Relevance | 5 | Highlights need for mental health integration in pain management — actionable but not novel |
| Population Reach | 8 | Chronic pain and frailty affect hundreds of millions of older adults globally |
| Implementation Speed | 5 | Mental health integration into pain management is feasible but requires workforce |
| Evidence Strength | 4 | Cross-sectional; mediation analysis assumptions; abstract-only |
Key quantitative result: Frailty associated with multisite chronic pain; mental health mediates part of the relationship (no OR/mediation proportion available). External validation: None. Main limitation: Cross-sectional; cannot establish directionality; abstract-only. Equity implications: Chronic pain disproportionately affects lower-income older adults with limited access to mental health services. Evidence Maturity: Exploratory — confirmed.
Article 30 — Axling et al. (2026) | PMID 42889170
Methylation Profiling in Small Intestinal Neuroendocrine Tumors ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Long-read whole-genome methylation in SI-NETs is technically novel; chr18 methylation beyond the affected chromosome is a new finding |
| Clinical Relevance | 4 | No therapeutic or diagnostic readout yet; mechanistic discovery stage |
| Population Reach | 3 | SI-NETs: ~3,000 new US cases/year — rare |
| Implementation Speed | 2 | Long-read WGS not in routine clinical use; years of translational work required |
| Evidence Strength | 5 | Long-read WGS methodology is technically sophisticated; abstract-only |
Key quantitative result: Chr18 status associated with widespread methylation differences linked to transcriptional programs relevant to SI-NET biology (no specific enrichment scores from abstract). External validation: None. Main limitation: Single study; abstract-only; no functional validation; translational distance is large. Equity implications: SI-NET patients often diagnosed late; molecular subtyping could eventually improve early identification. Evidence Maturity: Exploratory — confirmed.
Article 31 — Jin et al. (2026) | PMID 42891116
Single-Cell Multiomics Reveals Breast Cancer Cell Trajectories and Regulatory Networks ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Integration of scRNA-seq, gut microbiome, and regulatory network analysis in breast cancer is methodologically ambitious |
| Clinical Relevance | 3 | Preclinical discovery; SNAI1-ZEB1-FOXM1 networks require experimental validation; not clinically actionable |
| Population Reach | 7 | Breast cancer: most common cancer in women globally |
| Implementation Speed | 2 | Basic research stage; years from any clinical application |
| Evidence Strength | 3 | Single-study multiomics; classification_confidence = medium; no experimental validation |
Key quantitative result: SNAI1-ZEB1-FOXM1 coregulatory networks identified as candidate drivers (no functional validation metrics from abstract). External validation: None. Main limitation: Computational only; no experimental validation; gut microbiome integration adds interpretive complexity. Equity implications: Breast cancer disproportionately diagnosed later in low-income countries; molecular insights could eventually improve global outcomes. Evidence Maturity: Exploratory — confirmed.
Article 32 — Ding et al. (2026) | PMID 42890210
AI in Proton Therapy Treatment Planning: Narrative Review ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Narrative review of an active field; no new data |
| Clinical Relevance | 5 | Proton therapy planning is highly specialized; AI efficiency gains are meaningful for that context |
| Population Reach | 4 | Proton therapy available at ~100 centers globally; niche but growing |
| Implementation Speed | 3 | Physics-aware validation required; multi-institutional testing needed |
| Evidence Strength | 3 | Narrative review; no systematic methodology; no primary data |
Key quantitative result: AI is a key enabler of efficient, patient-specific proton therapy planning (no quantitative metrics from abstract). External validation: Not applicable (review). Main limitation: Narrative review; no systematic methodology; rapidly evolving field. Equity implications: Proton therapy is concentrated in high-income countries; AI efficiency gains will be inaccessible to most of the world. Evidence Maturity: Exploratory — confirmed.
Article 33 — Yamanouchi et al. (2026) | PMID 42890508
Four Pillars for T2D + CKD G4-G5: Clinical Review ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Four-pillar framework is established; review adds clinical guidance for CKD G4-G5, which is often excluded from trials |
| Clinical Relevance | 7 | CKD G4-G5 is the highest-risk, most undertreated segment; structured reinitiation guidance fills a real gap |
| Population Reach | 7 | ~800 million people globally have CKD; T2D + advanced CKD is a major subgroup |
| Implementation Speed | 7 | Review directly actionable in clinical practice; drugs are available |
| Evidence Strength | 4 | Clinical review; no primary data; but synthesizes robust trial evidence |
Key quantitative result: Clinical guidance on identifying and reinitiating missing pillars in CKD G4-G5 (no quantitative results from abstract). External validation: Based on synthesis of trial evidence. Main limitation: Review format; CKD G4-G5 is often excluded from pivotal trials; evidence base is extrapolated. Equity implications: Advanced CKD disproportionately affects racial minorities and low-income populations; guidance on implementing all four pillars could reduce outcome disparities. Evidence Maturity: Validated — confirmed for synthesized evidence base.
Article 34 — Li et al. (2026) | PMID 42888846
Allogeneic eDN70(-) CAR-T Cells: In Vitro Study ⚪ Promising but preliminary | In vitro
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Avoiding TCR/MHC editing while using eDN70(-) selection to reduce GVH/HVG is a genuinely novel engineering approach |
| Clinical Relevance | 3 | In vitro only; capped at 5 per protocol; early-stage preclinical |
| Population Reach | 6 | Allogeneic CAR-T would benefit all patients needing CAR-T therapy if off-the-shelf approach is validated |
| Implementation Speed | 2 | Lab stage; years from clinical translation |
| Evidence Strength | 3 | In vitro only; classification_confidence = medium; no in vivo data |
Key quantitative result: eDN70(-) UCAR-T cells overcome persistence limitations of conventional allogeneic CAR-T (no specific functional assay metrics from abstract). External validation: None. Main limitation: In vitro only; no animal models; no dual-target clinical validation. Equity implications: Off-the-shelf CAR-T could dramatically reduce cost and manufacturing time — a major equity advance if realized clinically. Evidence Maturity: Exploratory — confirmed.
Article 35 — Wu et al. (2026) | PMID 42889630
Bispecific NK-Cell Engager Targeting TP53 Mutation ⚪ Promising but preliminary | In vitro
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Targeting intracellular TP53 mutation via TCR-mimic antibody for NK cell engagement is highly innovative; addresses a historically undruggable target |
| Clinical Relevance | 3 | In vitro; capped at 5; TP53 mutations are common across cancers but translation is distant |
| Population Reach | 7 | TP53 mutations occur in ~50% of all cancers — massive theoretical reach |
| Implementation Speed | 2 | Early lab stage; years from clinical translation |
| Evidence Strength | 3 | In vitro only; classification_confidence = medium |
Key quantitative result: Bispecific NKCE enables tumor-specific NK cell-mediated killing of TP53-mutant cancer cells in vitro (no quantitative metrics from abstract). External validation: None. Main limitation: In vitro; peptide-MHC presentation of TP53 mutations is HLA-restricted — significant translational complexity. Equity implications: TP53-targeting could potentially benefit the broadest cancer population if translated. Evidence Maturity: Exploratory — confirmed.
Article 36 — Wong et al. (2026) | PMID 42890293
Telehealth and AI Acceptance for Prediabetes Lifestyle Modification: Qualitative Study ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Qualitative study on AI/telehealth acceptance is an important implementation science contribution but not scientifically novel |
| Clinical Relevance | 5 | Informs digital health deployment for prediabetes — a huge but modifiable population |
| Population Reach | 9 | Prediabetes affects ~380 million globally |
| Implementation Speed | 5 | Implementation science findings directly applicable to program design |
| Evidence Strength | 4 | Qualitative; limited transferability; abstract-only |
Key quantitative result: Conditional acceptance of AI telehealth when it complements human care (qualitative finding — no metrics applicable). External validation: Not applicable. Main limitation: Qualitative; single-setting; context-specific to participants' experience. Equity implications: Digital health interventions can exacerbate inequity if access to devices/internet is unequal; study should prompt attention to digital divide. Evidence Maturity: Exploratory — confirmed.
Article 37 — Cheng et al. (2026) | PMID 42891558
Endothelial Matrin-3 in Atherosclerosis: Murine Study ⬜ Standard | Animal model
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | First study of endothelial Matrin-3 in atherosclerosis; novel mechanistic pathway (senescence + lipid homeostasis) |
| Clinical Relevance | 3 | Animal model; capped at 5; no human data; early-stage mechanistic discovery |
| Population Reach | 8 | Atherosclerosis underlies the #1 killer globally; any validated target would have enormous reach |
| Implementation Speed | 1 | Lab/animal stage; years from human translation |
| Evidence Strength | 4 | Murine experimental; well-designed mechanistic study but species translation uncertainty; classification_confidence = medium |
Key quantitative result: Endothelial Matrin-3 deficiency associated with vascular alterations and systemic metabolic dysfunction in mice (no specific quantitative metrics from abstract). External validation: None. Main limitation: Animal model; human translation uncertain; abstract-only. Equity implications: Atherosclerosis has universal reach; a validated Matrin-3 target could eventually benefit populations globally. Evidence Maturity: Exploratory — confirmed.
Article 38 — He et al. (2026) | PMID 42891066
ctDNA in Diffuse Large B-Cell Lymphoma: Panoramic Review ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Narrative review of an active ctDNA-DLBCL field; does not advance primary knowledge |
| Clinical Relevance | 6 | ctDNA in DLBCL is clinically actionable; review is useful for practitioners |
| Population Reach | 5 | DLBCL is the most common aggressive lymphoma; ~25,000 new US cases/year |
| Implementation Speed | 5 | Some ctDNA approaches are clinically available for DLBCL now |
| Evidence Strength | 3 | Narrative review; no primary data; abstract-only; classification_confidence = medium |
Key quantitative result: None — narrative synthesis. External validation: Not applicable. Main limitation: Narrative review; no systematic methodology; translational challenges acknowledged. Equity implications: ctDNA testing for DLBCL monitoring requires infrastructure not universally available. Evidence Maturity: Exploratory — confirmed.
Article 39 — Yuti et al. (2026) | PMID 42890208
Anti-PD-L1 scFv-Secreting GD2-CAR T Cells in Retinoblastoma: In Vitro ⚪ Promising but preliminary | In vitro
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Fifth-generation CAR-T with integrated checkpoint blockade for a pediatric solid tumor is mechanistically innovative |
| Clinical Relevance | 3 | In vitro only; capped at 5; but retinoblastoma is a pediatric emergency where vision-saving therapy is urgently needed |
| Population Reach | 3 | Retinoblastoma: ~8,000 cases/year globally; very rare but devastating in children |
| Implementation Speed | 2 | In vitro stage; significant translational work required |
| Evidence Strength | 3 | In vitro proof-of-concept; classification_confidence = medium |
Key quantitative result: In vitro proof-of-concept for GD2-CAR-T with anti-PD-L1 secretion against GD2-low retinoblastoma (no specific cytotoxicity metrics from abstract). External validation: None. Main limitation: In vitro; no animal data yet; GD2-low antigen density poses a significant challenge. Equity implications: Retinoblastoma disproportionately results in blindness in LMICs due to late diagnosis; cell therapies would initially be inaccessible. Evidence Maturity: Exploratory — confirmed.
Article 40 — Yamamoto et al. (2026) | PMID 42888850
IL-12-Producing iPSC-Derived APCs for Off-the-Shelf Immunotherapy ⚪ Promising but preliminary | Animal/In vitro
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | iPSC-derived IL-12-producing APCs as a standardized off-the-shelf cancer vaccine platform is a meaningful advance over variable DC vaccines |
| Clinical Relevance | 3 | Animal/in vitro; capped at 5; but addresses a real clinical gap in DC vaccine consistency |
| Population Reach | 7 | If validated, could replace variable patient-derived DC vaccines across multiple cancer types |
| Implementation Speed | 2 | Animal stage; regulatory pathway for iPSC-derived products is complex |
| Evidence Strength | 3 | Murine in vitro; classification_confidence = medium |
Key quantitative result: iPSC-derived IL-12-APC system shows more consistent anti-tumor T cell activation than conventional DC vaccines (no specific metrics from abstract). External validation: None. Main limitation: Animal/in vitro only; iPSC manufacturing standardization is a major regulatory challenge. Equity implications: Off-the-shelf approach could reduce the cost and personalization barrier of DC vaccines — potentially increasing access. Evidence Maturity: Exploratory — confirmed.
Articles 41–45: Remaining articles (scores assigned)
Article 41 — Liao et al. (2026) | PMID 42890403
Herbal Medicine and Thrombocytopenia in AML Chemotherapy
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Nested case-control adds some rigor to TCMH literature; concept is established |
| Clinical Relevance | 4 | No mechanistic data; potential herb-drug interactions unaddressed |
| Population Reach | 5 | AML chemotherapy-induced thrombocytopenia affects most AML patients treated with cytotoxic therapy |
| Implementation Speed | 3 | Evidence insufficient for routine recommendation |
| Evidence Strength | 4 | Nested case-control is better than retrospective cohort; but significant confounding likely |
Evidence Maturity: Exploratory — confirmed.
Article 42 — Zhong et al. (2026) | PMID 42890729
Hypoparathyroidism Patient Challenges in China: Cross-Sectional Survey
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Patient-reported outcomes in Chinese HypoPT population; adds regional data to sparse literature |
| Clinical Relevance | 5 | Highlights unmet psychosocial needs; informs supportive care planning |
| Population Reach | 3 | Rare disease (~1:100,000); scored relative to unmet need |
| Implementation Speed | 4 | Findings inform counseling and support programs; no new treatment |
| Evidence Strength | 3 | Cross-sectional online survey; self-selection bias; abstract-only |
Evidence Maturity: Exploratory — confirmed.
Article 43 — George et al. (2026) | PMID 42889925
MCL Real-World Outcomes in Transplant-Ineligible Ontario Patients
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Real-world MCL data from Ontario; confirms known poor outcomes in transplant-ineligible patients |
| Clinical Relevance | 6 | Quantifies unmet need; useful for health technology assessment and trial design |
| Population Reach | 4 | MCL is rare (~4,500 new US cases/year) |
| Implementation Speed | 5 | Findings support advocacy for novel agents; near-term policy relevance |
| Evidence Strength | 5 | Real-world retrospective cohort; population-based database; moderate rigor |
Evidence Maturity: Validated — confirmed.
Article 44 — Jiang et al. (2026) | PMID 42888635
HIV-Related Mortality Trends in the US, 1999–2023
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Epidemiological trend analysis; updates existing surveillance data; not a conceptual breakthrough |
| Clinical Relevance | 6 | Identifies persistent disparities directly actionable through targeted HIV care programs |
| Population Reach | 6 | HIV affects ~1.2 million Americans; disparities affect millions more |
| Implementation Speed | 5 | Findings directly inform targeted public health intervention programs |
| Evidence Strength | 5 | Large CDC WONDER database; 25-year trend analysis; ecological design |
Evidence Maturity: Validated — confirmed.
Article 45 — Wu et al. (2026) (not to be confused with the Wu et al. NKCE paper) — Note: Article 45 in this analysis refers to Ding et al. already covered as Article 32.
Checking: The batch contains 45 articles; Articles 32–40 cover the remaining unique PMIDs. Articles 41–44 complete the set to 44 unique articles. The 45th unique article in the JSON is: